Tissue-based compositions

• US 9,238,090 B1
• Filed: 12/24/2014
• Issued: 01/19/2016
• Est. Priority Date: 12/24/2014
• Status: Active Grant

• Current Assignee: Fettech LLC
• Original Assignee: Fettech LLC
• Inventors: Fette, Clay
• Primary Examiner(s): UNDERDAHL, THANE E
• Application Number:
  US14/582,288
• Time in Patent Office: 391 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61L 2300/104 Silver, e.g. silver sulfadiazine
• CPC Class Codes: A61L 2300/404 Biocides, antimicrobial agents, antiseptic agents
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 27/3633 Extracellular matrix [ECM]
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 27/56 Porous materials, e.g. foams or sponges

Abstract

Compositions comprising extracellular matrix (ECM) materials and methods of use thereof are disclosed. The compositions may comprise two or more ECM materials derived from different types of tissues, such as, e.g., lung tissue and spleen tissue, formulated for administration to a patient or configured as a medical device for implantation in or application to the patient. The compositions may combine complementary properties of different types of ECM materials for customized patient-specific and/or site-specific tissue repair and/or regeneration.

Claims

1. A composition comprising:

spleen extracellular matrix in sheet form, the spleen extracellular matrix retaining native growth factors of spleen tissue, and retaining a native structure of the spleen tissue, such that the spleen extracellular matrix includes a reticular matrix structure derived from a reticular component of the spleen tissue; and

a second extracellular matrix, other than spleen extracellular matrix, the second extracellular matrix being integrated into the reticular matrix structure of the spleen extracellular matrix;

wherein the composition is configured for administration to a patient.

2. The composition of claim 1, wherein the second extracellular matrix is in particulate form.

3. The composition of claim 2, wherein the second extracellular matrix comprises lung extracellular matrix.

4. The composition of claim 1, wherein the second extracellular matrix is in gel form.

5. The composition of claim 1, wherein the composition is configured for application to native tissue of the patient for repairing the native tissue, and wherein the composition further comprises one or more antimicrobial agents, therapeutic agents, pharmaceutical agents, or a combination thereof.

6. The composition of claim 1, wherein the spleen extracellular matrix sheet is manipulated into a rod-like configuration, such that the composition has a rod-like shape.

7. The composition of claim 1, wherein the spleen extracellular matrix sheet is manipulated into a tubular configuration, such that the composition has a tubular shape.

8. The composition of claim 1, wherein at least a portion of the second extracellular matrix is in particulate form.

9. The composition of claim 2, wherein the composition includes at least two layers, at least one of the layers comprising the second extracellular matrix particulate embedded in the reticular matrix structure of the spleen extracellular matrix.

10. The composition of claim 1, further comprising at least one antimicrobial agent.

11. The composition of claim 10, wherein the at least one antimicrobial agent comprises ionic silver.

12. The composition of claim 2, wherein the spleen extracellular matrix has a native concentration of at least one growth factor that is higher than a native concentration of the at least one growth factor of the second extracellular matrix.

13. The composition of claim 12, wherein the at least one growth factor is chosen from vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF), or epidermal growth factor (EGF).

29. The composition of claim 1, wherein the spleen extracellular matrix retains at least one native growth factor of the spleen tissue chosen from vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF), or epidermal growth factor (EGF).

14. A composition comprising:

spleen extracellular matrix in sheet form, the spleen extracellular matrix retaining native growth factors of spleen tissue, and retaining a native structure of the spleen tissue, such that the spleen extracellular matrix includes a reticular matrix structure derived from a reticular component of the spleen tissue; and

a second extracellular matrix comprising at least one mammalian extracellular matrix chosen from lung extracellular matrix, gall bladder extracellular matrix, bone marrow extracellular matrix, pancreatic extracellular matrix, or liver extracellular matrix, the second extracellular matrix being integrated into the spleen extracellular matrix;

wherein the spleen extracellular matrix has a higher native growth factor content than the second extracellular matrix, and the second extracellular matrix is integrated into the reticular matrix structure of the spleen extracellular matrix;

wherein the spleen extracellular matrix is in a form different from a form of the second extracellular matrix;

and wherein the composition is configured for application to native tissue of a patient for repairing the native tissue.

15. The composition of claim 14, wherein the second extracellular matrix is in gel form.

16. The composition of claim 14, wherein the spleen extracellular matrix has a higher native concentration of vascular endothelial growth factor (VEGF) than the second extracellular matrix, and the second extracellular matrix has higher native concentration of elastin than the spleen extracellular matrix.

17. The composition of claim 14, wherein the spleen extracellular matrix has a higher native concentration of platelet-derived growth factor (PDGF) than the second extracellular matrix, and the second extracellular matrix has higher native concentration of fibroblast growth factor (FGF) than the spleen extracellular matrix.

18. The composition of claim 14, wherein the spleen extracellular matrix has a higher native concentration of epidermal growth factor (EGF) than the second extracellular matrix, and the second extracellular matrix has a higher native concentration of vascular endothelial growth factor (VEGF) than the spleen extracellular matrix.

19. A composition comprising:

spleen extracellular matrix in sheet form, the spleen extracellular matrix retaining native growth factors of spleen tissue, and retaining a native structure of the spleen tissue, such that the spleen extracellular matrix includes a reticular matrix structure derived from a reticular component of the spleen tissue; and

lung extracellular matrix;

wherein the composition includes at least two layers, at least one of the layers comprising the lung extracellular matrix integrated into the reticular matrix structure of the spleen extracellular matrix; and

wherein the composition is configured for application to native tissue of a patient for repairing the native tissue.

20. The composition of claim 19, wherein the reticular matrix structure of the spleen extracellular matrix comprises a macroscopic fibrous network with interstitial spaces, the lung extracellular matrix being embedded in the interstitial spaces.

21. The composition of claim 19, wherein the native structure of the spleen tissue retained by the spleen extracellular matrix includes an outer membrane of the spleen tissue, such that the spleen extracellular matrix includes a layer portion derived from the outer membrane of the spleen tissue.

22. The composition of claim 19, wherein the lung-extracellular matrix is in particulate form, gel form, or liquid form.

23. The composition of claim 21, wherein the spleen extracellular matrix sheet is manipulated into a rod-like configuration, such that the composition has a rod-like shape configured for implantation into the patient.

24. The composition of claim 19, further comprising a third extracellular matrix, wherein at least one of the layers of the composition comprises the third extracellular matrix in sheet form, and wherein the third extracellular matrix comprises lung extracellular matrix or spleen extracellular matrix.

25. The composition of claim 19, wherein the spleen extracellular matrix sheet is manipulated into a rod-like configuration, such that the composition has a rod-like shape.

26. The composition of claim 19, wherein the spleen extracellular matrix sheet is manipulated into a tubular configuration, such that the composition has a tubular shape.

27. A composition comprising:

spleen extracellular matrix in sheet form, the spleen extracellular matrix retaining native growth factors of spleen tissue, and retaining a native structure of the spleen tissue, such that the spleen extracellular matrix includes a reticular matrix structure derived from a reticular component of the spleen tissue coupled to a layer portion derived from an outer membrane of the spleen tissue; and

lung extracellular matrix in particulate form, gel form, or liquid form and is integrated into the spleen extracellular matrix;

wherein the composition is configured for application to native tissue of a patient for repairing the native tissue.

28. The composition of claim 27, wherein the lung extracellular matrix is at least partially integrated into the reticular matrix structure of the spleen extracellular matrix.

30. The composition of claim 27, further comprising an antimicrobial agent at least partially integrated into the reticular matrix structure of the spleen extracellular matrix.